ARTICLE | Product Development
Multicancer early detection tests: the view from ASCO23
Prospective studies provide reassuring signals of safety, but identifying the right target populations remains a challenge for proving clinical utility
June 12, 2023 11:49 PM UTC
Data at ASCO on multicancer early detection tests provide glimpses of the benefits and parameters of the risks of the blood-based screening strategy, while highlighting the importance of testing the right people at the right time. A clearer picture is expected to emerge from Grail’s 140,000-person U.K. trial, due to read out 1H24.
Multicancer early detection (MCED) tests designed to pick up signatures of any type of cancer present a broader opportunity to catch and treat disease than liquid biopsies for single cancer types, but face greater technical challenges in threading the needle between sensitivity and specificity...